Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-RG0051
Host Cell : CHO Size : >1x106 frozen cells/vial
| Cat. No. | CSC-RG0051 |
| Target Gene | OPRD1 |
| Gene Species | Homo sapiens (Human) |
| Abbr | CHO-HuOPRD1-SNAP |
| Alias | OPRD1, DOR-1, D-OR-1, delta opioid receptor 1, OPRD |
| Host Cell | CHO |
| Host Cell Species | Cricetulus griseus (Chinese hamster) |
| Applications |
1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Research on the mechanisms of GPCR-related diseases |
| Size | >1x106 frozen cells/vial |
| Stability | Validated for at least 10 passages |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Storage | Liquid nitrogen |
| Shipping | Dry ice |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Growth Properties | Adherent |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
| Gene Name | OPRD1 opioid receptor, delta 1 [ Homo sapiens ] |
| Gene Symbol | OPRD1 |
| Synonyms | OPRD1; opioid receptor, delta 1; delta-type opioid receptor; DOR-1; D-OR-1; delta opioid receptor 1; OPRD; |
| GeneID | 4985 |
| Uni ProtID | P41143 |
| Chromosome Location | 1p36.1-p34.3 |
| Function | G-protein coupled receptor activity; enkephalin receptor activity; protein binding; receptor activity; signal transducer activity; |
| Pathway | Class A/1 (Rhodopsin-like receptors), organism-specific biosystem; G alpha (i) signalling events, organism-specific biosystem; GPCR downstream signaling, organism-specific biosystem; GPCR ligand binding, organism-specific biosystem; GPCRs, Class A Rhodopsin-like, organism-specific biosystem; Neuroactive ligand-receptor interaction, organism-specific biosystem; Neuroactive ligand-receptor interaction, conserved biosystem; |
| MIM | 165195 |
The delta-opioid receptor, also known as delta opioid receptor or simply delta receptor, abbreviated DOR, is an opioid receptor that has enkephalins as its endogenous ligands. Activation of delta receptors produces some analgesia, although less than that of mu-opioid agonists. Many delta agonists may also cause seizures at high doses, although not all delta agonists produce this effect. Evidence for whether delta agonists produce respiratory depression is mixed; high doses of the delta agonist peptide DPDPE produced respiratory depression in sheep, but in tests on mice the non-peptide delta agonist SNC-80 produced respiratory depression only at the very high dose of 40 mg/kg. In contrast both the peptide delta agonist Deltorphin II and the non-peptide delta agonist (+)-BW373U86 actually stimulated respiratory function and blocked the respiratory depressant effect of the potent mu-opioid agonist alfentanil, without affecting pain relief. It thus seems likely that while delta opioid agonists can produce respiratory depression at very high doses, at lower doses they have the opposite effect, a fact that may make mixed mu/delta agonists such as DPI-3290 potentially very useful drugs that might be much safer than the mu agonists currently used for pain relief.
A: The Human OPRD1-SNAP Stable Cell Line-CHO offers several advantages for research into opioid receptor dynamics. Firstly, the stable expression of the opioid receptor delta-1 (OPRD1) in CHO cells allows for a controlled environment to study receptor function. Secondly, the SNAP tag enables the use of bioorthogonal chemistry for the site-specific labeling of the receptor, which can be used for visualization or affinity purification without disrupting native cellular functions. This allows researchers to track receptor movement, trafficking, and interactions with other cellular components in a more precise manner.
A: The cell line provides a platform for high-throughput screening of potential opioid analgesics. By stably expressing the OPRD1 receptor, researchers can test the efficacy and specificity of new compounds in a cell-based assay. The SNAP tag allows for the receptor to be tagged with fluorescent probes, which can be used to monitor the activity of the receptor in response to different drugs, aiding in the discovery of new analgesic compounds with improved efficacy and reduced side effects.
A: This cell line enables researchers to study the pharmacological properties of the OPRD1 receptor in a controlled environment. By exposing the cells to various ligands, researchers can investigate the receptor's binding affinity, activation, and desensitization. The SNAP tag allows for the receptor to be labeled with fluorescent probes, which can be used to visualize the receptor's activation in real-time, providing insights into the mechanism of action of opioids.
A: The stable expression of the SNAP-tagged OPRD1 receptor allows researchers to track the receptor's movement within the cell using fluorescence microscopy. This enables the study of receptor trafficking pathways, endocytosis, and recycling, which are critical for understanding the regulation of receptor activity and cellular signaling.
A: By providing a model system for studying the OPRD1 receptor, this cell line can help researchers identify genetic variations that affect receptor function. This information can be used to develop personalized treatment plans for patients with different responses to opioids, potentially improving therapeutic outcomes and reducing the risk of adverse effects.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.